TY - JOUR
T1 - ROLIPRAM IMPROVES COGNITION, REDUCES ANXIETY- AND DESPAIR-LIKE BEHAVIORS AND IMPACTS HIPPOCAMPAL NEUROPLASTICITY AFTER TRANSIENT GLOBAL CEREBRAL ISCHEMIA
AU - Soares, Ligia Mendes
AU - De Vry, Jochen
AU - Steinbusch, Harry W. M.
AU - Milani, Humberto
AU - Prickaerts, Jos
AU - Weffort De Oliveira, Rubia M.
PY - 2016/6/21
Y1 - 2016/6/21
N2 - Cognitive impairment, anxiety- and depressive like symptoms are well recognized outcome of cerebral ischemia in clinical and preclinical settings. Rolipram, a phosphodiesterase-4 (PDE-4) inhibitor, improves cognition and produces anxiolytic- and antidepressant-like effects in rodents. Rolipram also exerts anti-inflammatory effects and enhances survival of newborn hippocampal neurons in mice subjected to transient global cerebral ischemia. Here, we evaluated the effects of chronic rolipram treatment in mice subjected to transient global brain ischemia. C56136/7 mice were subjected to bilateral common carotid artery occlusion (BCCAO) and were then tested in a multi tiered behavioral battery including the elevated zero maze (EZM), open field (OF), object location test (OLT), and forced swim test (FST). We also investigated the effects of rolipram on hippocampal neurodegeneration and the expression of the neuronal plasticity markers doublecortin (DCX) and microtubule-associated protein (MAP-2). Ischemic mice exhibited memory deficits OLT, higher levels of anxiety EZM and behavioral despair FST. BCCAO caused neuronal loss in the CA3 hippocampal subfield and basolateral amygdale (BLA). In the hippocampus of BCCAO mice, a disrupted neuronal plasticity was evidenced by decreased DCX expression. Chronic treatment with rolipram attenuated the behavioral effects of BCCAO. Rolipram also decreased neurodegeneration in the CA3 while it increased dendritic arborization of DCX-immunoreactive (DCX-IR) neurons and microtubule associate MAP-2 expression in the hippocampus of BCCAO mice. These data suggest that chronic inhibition of PDE-4 can be a useful therapeutic strategy to improve the emotional and cognitive outcomes of transient global cerebral ischemia.
AB - Cognitive impairment, anxiety- and depressive like symptoms are well recognized outcome of cerebral ischemia in clinical and preclinical settings. Rolipram, a phosphodiesterase-4 (PDE-4) inhibitor, improves cognition and produces anxiolytic- and antidepressant-like effects in rodents. Rolipram also exerts anti-inflammatory effects and enhances survival of newborn hippocampal neurons in mice subjected to transient global cerebral ischemia. Here, we evaluated the effects of chronic rolipram treatment in mice subjected to transient global brain ischemia. C56136/7 mice were subjected to bilateral common carotid artery occlusion (BCCAO) and were then tested in a multi tiered behavioral battery including the elevated zero maze (EZM), open field (OF), object location test (OLT), and forced swim test (FST). We also investigated the effects of rolipram on hippocampal neurodegeneration and the expression of the neuronal plasticity markers doublecortin (DCX) and microtubule-associated protein (MAP-2). Ischemic mice exhibited memory deficits OLT, higher levels of anxiety EZM and behavioral despair FST. BCCAO caused neuronal loss in the CA3 hippocampal subfield and basolateral amygdale (BLA). In the hippocampus of BCCAO mice, a disrupted neuronal plasticity was evidenced by decreased DCX expression. Chronic treatment with rolipram attenuated the behavioral effects of BCCAO. Rolipram also decreased neurodegeneration in the CA3 while it increased dendritic arborization of DCX-immunoreactive (DCX-IR) neurons and microtubule associate MAP-2 expression in the hippocampus of BCCAO mice. These data suggest that chronic inhibition of PDE-4 can be a useful therapeutic strategy to improve the emotional and cognitive outcomes of transient global cerebral ischemia.
KW - rolipram
KW - bilateral common carotid artery occlusion
KW - neuroprotection
U2 - 10.1016/j.neuroscience.2016.03.062
DO - 10.1016/j.neuroscience.2016.03.062
M3 - Article
C2 - 27058148
SN - 0306-4522
VL - 326
SP - 69
EP - 83
JO - Neuroscience
JF - Neuroscience
ER -